New York City
Paula Zahn and Lady Lynn Forester de Rothschild. (Rob Rich)
- The Alzheimer's Drug Discovery Foundation held its second annual luncheon and symposium - "Hope on the Horizon: New Drugs for Alzheimer's Disease - at the Jumeirah Essex House on Wednesday, September 21, 2011. With Executive Chairs, Leonard A. Lauder
, Lynn Forester de Rothschild
, and Nancy
and Mel Goodes
, and Honorary Chairs Bonnie Pfeifer Evans
and Alice Shure
, the event brought together approximately 275 guests to raise $600,000 for Alzheimer's drug discovery research. Paula Zahn
, acclaimed journalist and newscaster was emcee. A door prize drawing raised over $50,000 and featured an Imperial Shih Tzu puppy, 100 percent of the proceeds from this event will be used to fund promising drug research and early clinical studies for Alzheimer's disease.
The Luncheon featured presentations focused on the urgency of finding breakthrough treatments to detect, prevent, and cure Alzheimer's and other neurodegenerative diseases. In the 11 a.m. presentation, Joan Sutton Straus
introduced Dr. Howard Fillit
, who presented a progress report on the development of Alzheimer's drugs. Leonard A. Lauder
, Co-Chairman of the Foundation, welcomed guests at the Luncheon. Bonnie Pfeifer Evans
and Alice Shure
, trustees of the Charles Evans Foundation, presented the inaugural Charles Evans Award for Excellence to Dr. Daniel Skovronsky
, Founder, President, and CEO of Avid Radiopharmaceuticals, Inc. This award recognizes individuals whose contributions have significantly advanced the field of Alzheimer's drug discovery. Following the award presentation, Zahn conducted an onstage interview with Dr. Eric Kandel
, distinguished neuroscientist, world-renowned researcher, and winner of the 2000 Nobel Prize in Physiology or Medicine. The luncheon concluded with special remarks from Mel Goodes
, former Chairman and CEO of Warner-Lambert.
Leonard Lauder and Beth Rudin deWoody. (Rob Rich)
"The Alzheimer's Drug Discovery Foundation has one goal - accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging," Foundation Executive Director Dr. Howard Fillit
said in remarks from the podium. "Our approach to research funding is not a traditional one. We are proactive, insist on accountability from our grantee partners, and we prioritize important work that other funders can't or won't support. We could not do this without our donors and are so grateful for your support."
"Our strategy is distinctive. We focus on innovative Alzheimer's drug research in biotechnology companies and at universities, financing programs to catapult successful projects to the next stage of development," Leonard A. Lauder told guests. "Investors with deeper pockets can then step forward to support our grantees in bringing new drugs to market and getting them in the hands of patients."
About The ADDF
Founded in 1998 by Leonard
and Ronald Lauder
, the ADDF awards grants to leading scientists conducting breakthrough drug discovery and early clinical research. The sole mission of the Foundation is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. To date, the ADDF has granted more than $50 million to fund over 340 Alzheimer's drug discovery programs and clinical trials at academic centers and biotechnology companies in 18 countries, 100 percent of funds raised are used directly for Alzheimer's drug research and related programs.
Leonard Lauder, Mari Skovronsky and Dr. Daniel Skovronsky. (Rob Rich)